Genome-wide expression analysis of therapy-resistant tumors reveals SPARC as a novel target for cancer therapy
Open Access
- 1 June 2005
- journal article
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 115 (6) , 1492-1502
- https://doi.org/10.1172/jci23002
Abstract
Overcoming resistance to chemotherapy and radiation therapy has been a difficult but important goal in the effort to cure cancer. We used gene-expression microarrays to identify differentially expressed genes involved in colorectal cancer resistance to chemotherapy and identified secreted protein, acidic and rich in cysteine (osteonectin) (SPARC) as a putative resistance-reversal gene by demonstrating low SPARC expression in refractory human MIP101 colon cancer cells. We were able to achieve restoration of their radiosensitivity and sensitivity to 5-fluorouracil and irinotecan by reexpression of SPARC in tumor xenografts. Moreover, treatment of mice with SPARC conferred increased sensitivity to chemotherapy and led to significant regression of xenografted tumors. The results show that modulation of SPARC expression affects colorectal cancer sensitivity to radiation and chemotherapy. SPARC-based gene or protein therapy may ameliorate the emergence of resistant clones and eradicate existing refractory clones and offers a novel approach to treating cancer.Keywords
This publication has 46 references indexed in Scilit:
- Matricellular protein SPARC is translocated to the nuclei of immortalized murine lens epithelial cellsJournal of Cellular Physiology, 2004
- p53 is an independent pre-treatment markers for long-term survival in stage II and III colorectal cancers: an analysis of interaction between genetic markers and fluorouracil-based adjuvant therapyCancer Letters, 2004
- SPARC regulates cell cycle progression in mesangial cells via its inhibition of IGF‐dependent signalingJournal of Cellular Biochemistry, 2002
- Retroviral transduction of human dihydropyrimidine dehydrogenase cDNA confers resistance to 5-fluorouracil in murine hematopoietic progenitor cells and human CD34+-enriched peripheral blood progenitor cellsCancer Gene Therapy, 2001
- SPARC (Secreted Protein Acidic and Rich in Cysteine) Induces Apoptosis in Ovarian Cancer CellsThe American Journal of Pathology, 2001
- Molecular Cloning and Characterization of Human Trabeculin-α, a Giant Protein Defining a New Family of Actin-binding ProteinsPublished by Elsevier ,1999
- Disruption of p53 in human cancer cells alters the responses to therapeutic agentsJournal of Clinical Investigation, 1999
- Requirement for p53 and p21 to Sustain G 2 Arrest After DNA DamageScience, 1998
- Distribution of SPARC in normal and neoplastic human tissue.Journal of Histochemistry & Cytochemistry, 1995
- SPARC antagonizes the effect of basic fibroblast growth factor on the igration of bovine aortic endothelial cellsJournal of Cellular Biochemistry, 1992